Biohaven (BHVN) Total Current Liabilities (2021 - 2026)
Biohaven (BHVN) posted Total Current Liabilities of $52.1 million for Q1 2026, down 55.08% sequentially from $115.9 million in Q4 2025, and down 68.25% YoY from $164.0 million in Q1 2025.
Analysis
Biohaven (BHVN) Total Current Liabilities (2021 - 2026) Analysis & Trends
Biohaven has reported Total Current Liabilities for 6 years, with the latest figure at $52.1 million in Q1 2026.
- Quarterly Total Current Liabilities fell 68.25% year-over-year to $52.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.1 million (down 68.25% YoY) and the FY2025 annual result came in at $115.9 million, down 24.83% from the prior year.
- Total Current Liabilities eased to $52.1 million in Q1 2026 per BHVN's latest filing, from $115.9 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $164.0 million in Q1 2025 and troughed at $28.4 million in Q3 2022.
- A 5-year average of $103.8 million and a median of $113.0 million in 2025 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Current Liabilities jumped 178.27% in 2024, then plunged 68.25% in 2026.
- Over 5 years, Total Current Liabilities stood at $90.0 million in 2022, then plunged by 38.43% to $55.4 million in 2023, then surged by 178.27% to $154.2 million in 2024, then dropped by 24.83% to $115.9 million in 2025, then sank by 55.08% to $52.1 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $52.1 million, $115.9 million, and $113.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 2.53 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 354.06 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 630.93 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Biohaven | 2.37 Bn | 2.10 Bn | - | 62.66 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 62.66 Mn |
| Mar 31, 2026 | 52.08 Mn |
| Dec 31, 2025 | 115.93 Mn |
| Sep 30, 2025 | 113.02 Mn |
| Jun 30, 2025 | 124.32 Mn |
| Mar 31, 2025 | 164.03 Mn |
| Dec 31, 2024 | 154.23 Mn |
| Sep 30, 2024 | 152.29 Mn |
| Jun 30, 2024 | 156.21 Mn |
| Mar 31, 2024 | 86.59 Mn |
| Dec 31, 2023 | 55.42 Mn |
| Sep 30, 2023 | 62.18 Mn |
| Jun 30, 2023 | 87.85 Mn |
| Mar 31, 2023 | 114.01 Mn |
| Dec 31, 2022 | 90.02 Mn |
| Sep 30, 2022 | 28.44 Mn |
| Dec 31, 2021 | 41.94 Mn |